Plunkett Research Online: CTI BioPharma Corp

CTI BIOPHARMA CORP (Subsidiary) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

CTI BioPharma Corp is a biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers. The company’s flagship product is VONJO (pacritinib), an oral kinase inhibitor approved for the treatment of certain adult patients with myelofib.....


CTI BIOPHARMA CORP

Ticker: Subsidiary
Exchange:
Parent Company:
Employees:
Fiscal Year Ends in

Phone: 206-282-7100
Fax: 206-284-6206
Address: 3101 Western Avenue, Ste .800
Seattle, WA 98121 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:
Parent Company: Sobi AB

Contacts Description

Guido OelkersCEO-Sobi
David KirskeCFO/Chief Accounting Officer/Executive VP/Secretary
See More
CTI BioPharma Corp is a biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers. The company’s flagship product is VONJO (pacritinib), an oral kinase inhibitor approved for the treatment of certain adult patients with myelofib.....See More See More

$USD, In whole numbers2023202220212020201920182017
Sales
Profits
Brands, Divisions and Affiliates Top Salaries
Salary
Bonus
Other Thoughts Corporate Culture